Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 2022 AR2

The report highlights Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.'s performance in 2022, achieving an operating income of RMB 70.79 billion, up 2.57% year-on-year. The company advanced its 'Great Southern TCM', 'Great Health', 'Great Commerce', and 'Great Medical Care' segments, including the completion of the Guangyao Wanglaoji Guangdong Lychee Industrial Park. In scientific innovation, the company's Ganoderma lucidum project won a gold medal at the Geneva International Exhibition of Inventions, and its subsidiary obtained FDA approval for BYS10 tablet clinical trials. Additionally, the company completed the acquisition of an additional 18.18% equity interest in GP Corp., increasing its shareholding to 90.92%.

Company: Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Sector: Health Care

Country: China

Year: 2022

Type: AR2

Pages: 391

Back to company

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 2022 Annual Report

Annual Report

The report highlights Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.'s performance in 2022, achieving an operating income of RMB 70.79 billion, up 2.57% year-on-year. The company advanced its 'Great Southern TCM', 'Great Health', 'Great Commerce', and 'Great Medical Care' segments, including the completion of the Guangyao Wanglaoji Guangdong Lychee Industrial Park. In scientific innovation, the company's Ganoderma lucidum project won a gold medal at the Geneva International Exhibition of Inventions, and its subsidiary obtained FDA approval for BYS10 tablet clinical trials. Additionally, the company completed the acquisition of an additional 18.18% equity interest in GP Corp., increasing its shareholding to 90.92%.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2022

Reporting Period

Jan 1, 2022 - Dec 31, 2022

Fiscal Year

2022

Type

Annual Report with Sustainability Disclosures

Language

English

Pages

 

File Size

 

Standards & Assurance

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Employees